Clinical Situation: Newly Diagnosed

First-line treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Overall Survival (months)

The length of time where half the patients in the study are still alive

No Prior Therapies

First-line treatment with/without extended (maintenance) treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Overall Survival (months)

The length of time where half the patients in the study are still alive

No Prior Therapies

First-line treatment

For more detailed information, please click on the clinical trial ID number.

Drug Class Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Standard of Care Chemotherapy
Chemotherapy GOG-158 III Carboplatin, Cisplatin, Paclitaxel Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study.

No PFS or OS difference between cisplatin+paclitaxel and carboplatin+paclitaxel in optimally debulked stage III patients

CisPt+Pac vs CarboPt+Pac:

PFS: 19.4 vs 20.7 months
OS: 48.7 vs 57.4 months

pub 2003

Chemotherapy GOG-172 III Cisplatin, Paclitaxel Randomized phase III study of intravenous (IV) paclitaxel and cisplatin vs. IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172).

PFS and OS increased with IP treatment in optimally debulked stage III patients, but IP had more severe side effects

CisPt+Pac (IV) vs CisPt+Pac (IP):

PFS: 18.3 vs 23.8 months*
OS: 49.7 vs 65.6 months*

pub 2006

Chemotherapy NCT00326456; MITO-2 III Carboplatin, Liposomal doxorubicin, Paclitaxel Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer

No significant PFS or OS difference when paclitaxel or liposomal doxorubicin is added to carboplatin, but different toxicity profiles

CarboPt+Pac vs CarboPt+PLD:

PFS: 16.8 vs 19.0 months
OS: 53.2 vs 61.6 months

pub 2011

Drugs in Clinical Development
Hormonal Therapy: Aromatase Retrospective Study: Adjuvant Hormone Therapy in LGSC Two sites Anastrozole, Letrozole, Tamoxifen Primary cytoreductive surgery and adjuvant hormone therapy in women with advanced low-grade serous carcinoma: Reducing overtreatment without compromising survival?

Promising PFS and OS in Low Grade Serous Cancer patients treated with hormone therapy following cytoreductive surgery

PFS: Not Reached (41 months follow up)
OS: Not Reached (41 months follow up)

Pub 2017

Hormonal Therapy: Anti-Estrogens Retrospective Study: Adjuvant Hormone Therapy in LGSC Two sites Anastrozole, Letrozole, Tamoxifen Primary cytoreductive surgery and adjuvant hormone therapy in women with advanced low-grade serous carcinoma: Reducing overtreatment without compromising survival?

Promising PFS and OS in Low Grade Serous Cancer patients treated with hormone therapy following cytoreductive surgery

PFS: Not Reached (41 months follow up)
OS: Not Reached (41 months follow up)

Pub 2017

Immunotherapy: Antibodies/CA125 NCT01616303 II Carboplatin, Oregovomab, Paclitaxel Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma

Addition of oregovomab enhances the outcomes achievable with carboplatin+paclitaxel alone

CarboPt+Pac+Ore vs CarboPt+Pac:

RFS: Not reached vs 15.4 months*
OS: Not reached vs 38.3 months*

abs Jun 2017

*Statistically significant result

First-line treatment with/without extended (maintenance) treatment

For more detailed information, please click on the clinical trial ID number.

Drug Class Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Standard of Care Targeted Drugs
Angiogenesis Inhibitors: VEGF NCT00262847; GOG-218 III Bevacizumab, Carboplatin, Paclitaxel Prescribing Information A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG218)

Improved PFS with addition of bevacizumab to carboplatin+paclitaxel, particularly those with ascites

CarboPt+Pac+Bev w/ Bev maint vs CarboPt+Pac+Bev vs CarboPt+Pac:

All:
PFS: 14.1 vs 11.2 vs 10.3 months*
OS: 43.3 vs 40.8 vs 41.1 months
With ascites:
PFS: 15.2 vs 10.3 months*
OS: 43.3 vs 39.9 months*

pub 2015; abs Jun 2018

Angiogenesis Inhibitors: VEGF NCT00483782; ICON7 III Bevacizumab, Carboplatin, Paclitaxel Prescribing Information ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer

Improved PFS and OS with addition of bevacizumab to carboplatin+paclitaxel in high risk patients

CarboPt+Pac+Bev w/ Bev maint vs CarboPt+Pac:

All:
PFS: 19.9 vs 17.5 months
OS: 45.5 vs 44.6 months (restricted mean survival)
High risk:
PFS: 16.0 vs 10.5 months*
OS: 39.3 vs 34.5 months* (restricted mean survival)

pub 2011; 2015

Angiogenesis Inhibitors: VEGF NCT00951496; GOG-252 III Bevacizumab, Carboplatin, Cisplatin, Paclitaxel A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

Compared to the IV reference arm, PFS was not significantly increased with either IP regimen

IV CarboPt+Pac+Bev w/ Bev maint vs IP CarboPt+Pac+Bev w/ Bev maint vs IP CisPt+Pac+Bev w/ Bev maint:

PFS: 24.9 vs 27.4 vs 26.2 months
OS: 75.5 vs 78.9 vs 72.9 months

pub 2019

*Statistically significant result

< Return to Clinical Situation

< Return to Clinical Trial Results Homepage